GSK’s Q2 revenue came in line with our expectations, but was marginally ahead of the street. Pharma remained mediocre, consumer health was steady and vaccines robust. Guidance for the year was upgraded. Apart from reiterating the decision to keep the group intact, GSK announced some strategic decisions – a restructuring programme with annual cost savings of £400m by 2021, R&D focused on immune system and genetics and a collaboration with 23andMe for research in genetics.
26 Jul 2018
Strong results as drugs and data get priority; Nucala rejected by Adcom
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong results as drugs and data get priority; Nucala rejected by Adcom
GSK plc (GSK:LON) | 1,652 189.9 0.7% | Mkt Cap: 68,453m
- Published:
26 Jul 2018 -
Author:
Kamla Singh -
Pages:
4
GSK’s Q2 revenue came in line with our expectations, but was marginally ahead of the street. Pharma remained mediocre, consumer health was steady and vaccines robust. Guidance for the year was upgraded. Apart from reiterating the decision to keep the group intact, GSK announced some strategic decisions – a restructuring programme with annual cost savings of £400m by 2021, R&D focused on immune system and genetics and a collaboration with 23andMe for research in genetics.